CLNN241220P2000
- 0.00
- 0.000.00%
Clene Newsroom
H.C. Wainwright Maintains Clene(CLNN.US) With Buy Rating, Maintains Target Price $31
Strategic Advancements and Robust Trial Design Drive Buy Rating for Clene
Clene Unveils Phase 3 Trial Design at NEALS
Benchmark Co. Sticks to Their Buy Rating for Clene (CLNN)
IBN Coverage: Clene (NASDAQ: CLNN) Announces Participation at Two Upcoming Investor Conferences
Clene to Present at Upcoming October Conferences
Clene Independent Chairman of the Board Acquires 26% More Stock
Express News | Clene Inc. : Canaccord Genuity Cuts Target Price to $86 From $94
Clene Insider Bought Shares Worth $438,458, According to a Recent SEC Filing
Clene Price Target Maintained With a $23.00/Share by EF Hutton
IBN Coverage: Clene (NASDAQ: CLNN) Announces Series of Direct Offerings, Concurrent Private Placements
Clene Announces Closing of $7.3 Million Registered Direct Offering and Concurrent Private Placements and Amendment of Debt Facility
Express News | Clene Inc. - Under Amendment, October 1 Principal Payment Decreased to $2 Mln
Express News | Clene Inc. - Co, Unit Enters Third Amendment to Loan and Security Agreement
Express News | Clene Inc. - Warrants Exercise Price $4.82, Immediately Exercisable, Expire in 5 Years
Express News | Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules
Analysts Are Bullish on These Healthcare Stocks: Clene (CLNN), I-MAB (IMAB)
Maxim Group Maintains Clene(CLNN.US) With Buy Rating, Maintains Target Price $20
Clene's CNM-Au8 Shows Promise in ALS Treatment Despite Trial Setbacks: A Strong Buy Recommendation
Clene Is Maintained at Buy by EF Hutton